Dr. Umar

This study generated a comprehensive set of gut metagenome-assembled genomes, revealing reduced Ruminococcus bromii diversity and loss of key metabolic genes in Parkinson’s disease, along with altered abundances of specific taxa and functional elements, providing valuable insights for microbiome signature databases and clinical research in PD.

This review article examines how transition metals shape bacterial virulence through three interconnected processes: acquisition, limitation, and intoxication. It emphasizes the evolutionary “arms race” between microbial strategies for metal uptake and host mechanisms for nutritional immunity. The review highlights how iron, zinc, and manganese—critical cofactors for bacterial metabolism—are sequestered, restricted, or weaponized […]

This review explores how dietary fiber influences microbiome activity, uremic toxins, inflammation, and clinical outcomes in CKD, highlighting substantial benefits and the need for individualized, fiber-rich dietary approaches.

This review explains how uremic toxins in ESRD drive cardiovascular, immune, and neurological injury, emphasizing toxin classification, toxicity indices, and the superiority of hemoadsorption and advanced membranes for removing hard-to-clear solutes.

This review evaluates how clinical events during the transition from pre-ESRD to ESRD influence outcomes, highlighting fluid overload, abrupt eGFR decline, and cardiovascular stress as major determinants of early ESRD mortality.

This meta-analysis of shotgun gut microbiome datasets in Parkinson’s disease identified cross-country microbial and functional signatures, including reduced riboflavin and biotin biosynthesis, depleted SCFA and polyamine levels, and species-level taxonomic shifts—highlighting microbiome-driven metabolic deficits as potential contributors to PD pathogenesis.

This study compared causes of death in ESRD patients between USRDS and KPSC sources, finding low concordance and highlighting limitations in mortality attribution for clinical and translational research contexts.

The KDIGO 2012 CKD guideline synthesizes global evidence to refine CKD definition, staging, prognosis, and management, emphasizing albuminuria and GFR as core predictors of progression and mortality.

End-stage renal disease is the irreversible loss of kidney function marked by uremic toxin accumulation, systemic complications, and the need for dialysis or transplantation. Its pathophysiology involves nephron loss, inflammation, metabolic disruption, and microbiome-derived toxins that accelerate cardiovascular and immune dysfunction.

A synthesis of modular nephron replacement strategies, detailing organoids, iBKs, bioprinting, and scaffolds, with emphasis on vascularization challenges and hybrid system potential.

This review examines how the chronic kidney disease gut microbiome becomes dysbiotic, elevates uremic toxins, weakens the gut barrier, and accelerates renal and cardiovascular injury, highlighting therapeutic targets.

This study shows how microbiome-derived IS and PCS drive renal fibrosis by activating the renal renin–angiotensin–aldosterone system associated epithelial-to-mesenchymal transition, amplifying TGF-β/Smad signaling and EMT features, and how losartan reduces this toxin-induced injury

Early diabetes complications dramatically increased five-year dialysis risk, with severity measured by DCSI strongly predicting renal decline.

End-stage renal disease microbiome is framed in this StatPearls narrative review as the clinical endpoint of chronic kidney disease, integrating guideline-based staging, epidemiology, complications, and management. The chapter summarizes KDIGO criteria, registry data on ESRD burden, and guidance on renal replacement preparation. Although the review does not profile gut or oral microbial […]

CKD increases blood lead and cadmium concentrations while reducing urinary elimination, heightening susceptibility to heavy metal toxicity in CKD, with disproportionately greater effects in Black Americans.

Hemodialysis patients showed higher caries burden and a marked shift toward acidogenic, aciduric supragingival microbiota, including elevated S. mutans and Lactobacillus species, indicating heightened caries vulnerability despite increased salivary pH and urea.

This pilot study identified reduced microbial diversity and a Proteobacteria-enriched blood microbiome profile in CKD, with microbial shifts correlating to kidney function, suggesting potential biomarker value.

Early CKD shows reduced SCFA-producing species and altered microbial metabolic pathways despite stable overall diversity, indicating subtle but clinically relevant microbiome disruption.

This study integrates long-read microbiome profiling with untargeted metabolomics to characterize distinct dysbiosis and metabolite alterations across diabetic, hypertensive, and non-comorbid CKD. The findings reveal robust species–metabolite networks that differentiate CKD subtypes with high diagnostic performance, underscoring their potential as early biomarkers of renal dysfunction and etiologically specific pathophysiology.

Bacteria regulate transition metal levels through complex mechanisms to ensure survival and adaptability, influencing both their physiology and the development of antimicrobial strategies.

This study links low-level heavy metal exposure to increased CKD risk and higher cadmium-associated mortality, with synergistic toxicity when both metals are elevated.

Study of chronic kidney disease microbiome resistance showing metal–antibiotic co-resistance, early-stage enrichment of Firmicutes/Proteobacteria, and progressive loss of resistance genes as CKD advances.

This study analyzed how low-level heavy metal exposures influence CKD risk and identified α-klotho as a mechanistic mediator, highlighting cadmium’s nephrotoxicity and complex mixture effects.

This study evaluated how serum uric acid levels relate to infection outcomes in ICU patients and found that uric acid reflects renal and metabolic stress rather than prognosis.